PRESS-RELEASE ·Filed May 4, 2026
Press release: fda
Actionable Insight • Neutral
Wait for topline results on May 5 before taking a position. Positive data could expand aficamten's label significantly, while negative results would be a major setback.
Final — all horizons settled through T+60d ⚠ clustered
CYTK ▲ +4.32% at T+60d
NEUTRAL call ✓ call won +4.32% · α vs SPY +1.58% · entry $77.09 → $80.42
T+1d
0.00%
call 0.00% · α -1.38%
$77.09
settled 5mo ago
T+5d
-3.28%
call -3.28% · α -5.27%
$74.56
settled 5mo ago
T+20d
-8.02%
call -8.02% · α -12.97%
$70.91
settled 4mo ago
T+60d
+4.32%
call +4.32% · α +1.58%
$80.42
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Cytokinetics announced it will report topline results from its ACACIA-HCM trial (aficamten in non-obstructive HCM) on May 5, 2026, with a conference call to follow. No results were disclosed in this press release.
Key Facts
- Topline results from Phase 3 ACACIA-HCM trial to be reported May 5, 2026
- Trial evaluates aficamten in patients with non-obstructive hypertrophic cardiomyopathy
- Conference call scheduled for 8:00 AM ET on May 5
Financial Impact
No financial data disclosed; impact depends on trial results
Risk Factors
- Trial may fail to meet primary endpoint
- Stock likely to be volatile around data release
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (26 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287103 |
32 reports for CYTK
89% Hit rate best @ T+20▲ +10.38%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $69.31 $67.59 | ▲ +2.48% | ▲ +4.59% | $65.60 (+5.35%) |
Sep 11, 2026 20d ago | Insider Cluster | $72.45 $67.56 | ▼ −6.75% | ▼ −6.86% | $65.60 (−9.45%) |
Sep 1, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 31, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 29, 2026 4w ago | Press Release | $70.91 $75.35 | ▲ +6.26% | ▲ +6.40% | $65.60 (−7.49%) |
Aug 28, 2026 5w ago | 8-K | $72.09 $72.72 | ▲ +0.87% | ▲ +0.76% | $65.60 (−9.00%) |
Jul 30, 2026 9w ago | Insider Cluster | $80.42 $81.37 | ▲ +1.18% | ▼ −2.44% | $65.60 (−18.43%) |
Jul 27, 2026 9w ago | Insider Cluster | $80.62 $77.13 | ▼ −4.33% | ▼ −5.40% | $65.60 (−18.63%) |
Jul 23, 2026 10w ago | Press Release | $80.74 $80.42 | ▼ −0.40% | ▼ −0.77% | $65.60 (−18.75%) |
Jul 14, 2026 11w ago | Insider Cluster | $81.93 $79.11 | ▼ −3.44% | ▼ −2.15% | $65.60 (−19.93%) |
Showing 10 of 32
US Market Status
Market Closed — Opens Mon (65h 6m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access